Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · IEX Real-Time Price · USD
1.560
-0.020 (-1.27%)
At close: Apr 19, 2024, 4:00 PM
1.520
-0.040 (-2.56%)
After-hours: Apr 19, 2024, 4:05 PM EDT
Cue Biopharma Stock Forecast
CUE's stock price has decreased by -54.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 9.50, with a low estimate of 6.00 and a high estimate of 15. The average target predicts an increase of 508.97% from the current stock price of 1.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
Buy | 3 | 3 | 3 | 3 | 3 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +412.82% | Apr 9, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +541.03% | Apr 9, 2024 |
Piper Sandler | Piper Sandler | Buy Reiterates $8 | Buy | Reiterates | $8 | +412.82% | Apr 3, 2024 |
Jefferies | Jefferies | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +284.62% | Mar 13, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +412.82% | Nov 6, 2023 |
Financial Forecast
Revenue This Year
4.04M
from 5.49M
Decreased by -26.41%
Revenue Next Year
4.04M
from 4.04M
EPS This Year
-1.34
from -1.11
EPS Next Year
-1.85
from -1.34
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 4.2M | 4.2M | 91.9M | 109.4M | 222.5M |
Avg | 4.0M | 4.0M | 35.1M | 94.5M | 185.4M |
Low | 3.9M | 3.9M | 5.5M | 81.4M | 152.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -23.5% | 4.0% | 2,174.1% | 211.9% | 135.3% |
Avg | -26.4% | - | 767.8% | 169.7% | 96.1% |
Low | -28.6% | -3.0% | 36.7% | 132.2% | 60.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.40 | -1.92 | -1.20 | -0.54 | 0.65 |
Avg | -1.34 | -1.85 | -1.24 | -0.52 | 0.63 |
Low | -1.30 | -1.79 | -1.29 | -0.50 | 0.61 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.